SENP1 and posterior cortical atrophy: Hopefully, progression of a selective inhibitor of either SENP1 or SENP3 to in vivo testing as well as in the setting of a dedicated clinical trial might lead to an effective therapeutic approach to restoring balance to the aberrant SUMO pathway of PCa patients.